All In Biotech

Drug Trial Radar · NCT01904409

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis

Last checked: Nov 19, 2026Latest source record: Oct 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

420

Actual

Start

Jun 2013

Primary completion

Jun 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Jul 22, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or hospitalization, in subjects with early decompensated liver cirrhosis. Rifaximin, a non-systemic antibacterial agent, is currently marketed as a 550 mg tablet for the reduction in risk of recurrent overt hepatic encephalopathy, a complication of liver cirrhosis. The rifaximin SSD tablet was formulated to maximize the efficacy of rifaximin. Subjects will receive 1 of 5 doses of rifaximin SSD tablets or placebo tablets every day for 24 weeks.

Conditions

  • Liver Cirrhosis

Interventions

  • PlaceboDrug

  • Rifaximin SSD 40 mg IR tabletDrug

  • Rifaximin SSD 80 mg IR tabletDrug

  • Rifaximin SSD 40 mg SER tabletDrug

  • Rifaximin SSD 80 mg SER tabletDrug

  • Rifaximin SSD 80mgIR/80mgSER tabletDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to all-cause mortality or hospitalization that is attributable to complications of liver disease.Time frame: Weeks 1 through 24

Locations

120 sites in 2 countries. Site status is shown where the registry gives one.

  • Salix Investigative Site

    Birmingham, Alabama

  • Salix Investigative Site

    Dothan, Alabama

  • Salix Investigative Site

    Mobile, Alabama

  • Salix Investigative Site

    Tucson, Arizona

  • Salix Investigational Site

    Artesia, California

  • Salix Investigational Site

    Bakersfield, California

  • Salix Investigational Site

    Chula Vista, California

  • Salix Investigational Site

    Coronado, California

  • Salix Investigational Site

    Costa Mesa, California

  • Salix Investigative Site

    Fresno, California

  • Salix Investigational Site

    La Jolla, California

  • Salix Investigative Site

    Los Angeles, California

  • Salix Investigational Site

    Monterey, California

  • Salix Investigational Site

    Riverside, California

  • Salix Investigational Site

    San Diego, California

  • Salix Investigational Site

    Ventura, California

  • Salix Investigational Site

    Englewood, Colorado

  • Salix Investigational Site

    Littleton, Colorado

  • Salix Investigational Site

    Bristol, Connecticut

  • Salix Investigational Site

    New Haven, Connecticut

  • Salix Investigational Site

    Waterbury, Connecticut

  • Salix Investigational Site

    Coral Gables, Florida

  • Salix Investigational Site

    Gainesville, Florida

  • Salix Investigative Site

    Hialeah, Florida

  • Salix Investigational Site

    Hialeah, Florida

  • Salix Investigational Site

    Hollywood, Florida

  • Salix Investigative Site

    Inverness, Florida

  • Salix Investigational Site

    Lake Worth, Florida

  • Salix Investigative Site

    Largo, Florida

  • Salix Investigative Site

    Maitland, Florida

  • Salix Investigational Site

    Miami, Florida

  • Salix Investigational Site

    Miami, Florida

  • Salix Investigational Site

    Miami, Florida

  • Salix Investigational Site

    Miami Springs, Florida

  • Salix Investigational Site

    New Port Richey, Florida

  • Salix Investigative Site

    Orlando, Florida

  • Salix Investigational Site

    Pembroke Pines, Florida

  • Salix Investigational Site

    Port Orange, Florida

  • Salix Investigational Site

    Saint Cloud, Florida

  • Salix Investigational Site

    Tamarac, Florida

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.